MEDIPATTERN CORP. 
By TORONTO, ONTARIO--(Marketwire - June 17, 2011) -
Attention: Business/Financial Editors
The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI - News), a pioneer in the development of medical imaging software solutions that help medical practitioners in better understanding lesions and critical anatomy, congratulates the research team led by Francis J. Porreca, MD, FACS, RVPI, Director of Vascular Surgery, Weiler Division of Montefiore Medical Center and The University Hospital of the Albert Einstein College of Medicine, and co-authors Angela Rodriguez-Wong, MD, RVT, RVPI and Joseph P. Hughes RVT, RVS both of Navix Diagnostix, Inc. on their paper entitled "Three Dimensional Reconstruction of the Vessel Lumen as an Adjunct to the Cerebrovascular Duplex Evaluation" which was presented Thursday in Chicago at the Annual Vascular Meeting. The Annual Vascular Meeting is a joint meeting for the Society for Vascular Surgeons (SVS) and the Society for Vascular Ultrasound (SVU) and is generally regarded as an important forum for discussing leading edge techniques and technologies that advance vascular practice. The paper compared Color Flow Doppler Ultrasound (CFDU) to standard 2D grayscale ultrasound using Visualize:Vascular(TM) to render 3D visualization of carotid arteries.
"In today's market where new technologies seem to come and go very quickly, it's exciting to be part of a technology that will aide in the care of patients with vascular disease and has the potential to have a positive impact on patient care," commented Dr. Porreca.
Current standard practice uses Doppler ultrasound to measure the velocity of the flow of blood through the carotid artery, where Stenosis (blockage and narrowing of the carotid artery) is inferred based upon the measurements. Visualize:Vascular segments the lumen (the active pathway for blood to flow within an artery) and then reconstructs the lumen in 3D providing an interactive view of the active pathway for the blood. The measurements within Visualize:Vascular are derived from the 2D frames captured using an image acquisition protocol which enables the 3D rendering and provides either diameters or cross sectional areas at the minimum and maximum points in the lumen.
The paper finds that 3D reconstruction technology using Visualize:Vascular produced a statistically significant correlation between the two techniques which can be used to calculate the reduction in the lumen. The team compared luminal reduction as calculated by Visualize:Vascular with Stenosis as inferred from velocity measurements. There was 99% (n=79, p = less than 0.001) correlation between velocity estimates and 3D visualization for estimating diameter reduction. Correlation for cases with less than 50% diameter reduction by duplex was 100% (n = 66, p = less than 0.004), while correlation for cases with 50% or greater diameter reduction by duplex was 92% (n = 13, p =less than 0.03). While more investigation with a larger group of patients is necessary, 3D reconstruction may be a valuable adjunct and may enhance the diagnostic capabilities of Color Flow Doppler Ultrasound (CFDU) the paper concludes.
"Medipattern congratulates the team for this fine work," commented Jeff Collins, President and CEO of The Medipattern Corporation. "The paper shows that Visualize:Vascular is a very credible technology because it correlates closely to the industry standard used most commonly for finding Stenosis today. The research team believes that the luminal reduction values calculated by Visualize:Vascular, along with the ability to view the lumen in 3D, provides meaningful insight into the health of the artery for these patients. We look forward to continuing to work with Dr. Porreca's group to continue to find additional applications for this technology."
2011 Upcoming Events:
-- Society of Vascular Surgery (SVS) Annual Meeting, Chicago June 16- 18 -- Society of Vascular Ultrasound (SVU) Annual Meeting, Chicago June 16-18
About The Medipattern Corporation:
Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Medipattern uses its Cadenza(TM) technology to process images, finding the salient region of interest and presenting them in 2D and 3D formats that enhance the reader's perception. For more information, please visit the Company's website: www.medipattern.com.
B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.
Forward-looking statements
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Jeff Collins The Medipattern Corporation CEO (416) 744-0009 ext. 224www.medipattern.com Kevin O'Connor Spinnaker Capital Markets Inc. (416) 962-3300 ext. 226